$522 Million is the total value of Ally Bridge Group (NY) LLC's 32 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDVL | MEDAVAIL HOLDINGS INC | $40,891,000 | -7.0% | 2,920,780 | 0.0% | 7.84% | +4.1% | |
| NTLA | INTELLIA THERAPEUTICS INC | $18,057,000 | +47.5% | 225,000 | 0.0% | 3.46% | +65.0% | |
| RGEN | REPLIGEN CORP | $16,039,000 | +1.5% | 82,500 | 0.0% | 3.08% | +13.5% | |
| COGT | UNUM THERAPEUTICS INC | $14,246,000 | -21.8% | 1,622,591 | 0.0% | 2.73% | -12.6% | |
| ITOS | ITEOS THERAPEUTICS INC | $11,033,000 | +1.1% | 322,794 | 0.0% | 2.12% | +13.0% | |
| ORIC | ORIC PHARMACEUTICALS INC | $10,120,000 | -27.6% | 413,061 | 0.0% | 1.94% | -19.0% | |
| APLS | APELLIS PHARMACEUTICALS INC | $9,869,000 | -25.0% | 230,000 | 0.0% | 1.89% | -16.1% | |
| APTOSE BIOSCIENCES INC | $8,420,000 | +36.4% | 1,409,150 | 0.0% | 1.61% | +52.6% | ||
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $6,507,000 | +4.6% | 150,000 | 0.0% | 1.25% | +17.1% | |
| SBTX | SILVERBACK THERAPEUTICS INC | $5,610,000 | -5.8% | 128,572 | 0.0% | 1.08% | +5.4% | |
| ORTX | ORCHARD THERAPEUTICS PLCads | $3,974,000 | +68.0% | 547,427 | 0.0% | 0.76% | +88.1% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MEDAVAIL HOLDINGS INC | 11 | Q2 2023 | 8.9% |
| UNUM THERAPEUTICS INC | 8 | Q3 2022 | 7.3% |
| RAPID MICRO BIOSYSTEMS INC-A | 8 | Q2 2023 | 3.5% |
| FATE THERAPEUTICS INC | 7 | Q2 2022 | 5.8% |
| VIRIDIAN THERAPEUTICS INC | 7 | Q2 2023 | 6.8% |
| SYROS PHARMACEUTICALS INC | 7 | Q2 2022 | 4.9% |
| REPLIGEN CORP | 7 | Q4 2022 | 6.5% |
| NAUTILUS BIOTECHNOLOGY INC | 7 | Q4 2022 | 3.8% |
| ARVINAS INC | 6 | Q1 2022 | 7.5% |
| NUVATION BIO INC | 6 | Q2 2022 | 4.9% |
View Ally Bridge Group (NY) LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cogent Biosciences, Inc. | November 19, 2020 | 1,420,500 | 8.0% |
View Ally Bridge Group (NY) LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-21 |
| 13F-HR | 2023-05-15 |
| 4 | 2023-03-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
View Ally Bridge Group (NY) LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.